Title: TREATMENT OF CANCER WITH NOVEL ANTI-IL 13 MONOClonAL ANTIBODIES

Abstract: The present invention relates to the treatment of IL13 dependent neoplastic disorders comprising the administration of novel anti-IL13 antibodies. The invention also includes diagnosing such tumors or cancer using the antibodies of the present invention to detect overexpression of IL13 in the patient.
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**
- IPC(7) : C07K 16/00; A61K 39/05; G01N 33/53
- US CL. : 424/130.1, 133.1, 155.1, 156.1; 530350, 387.3, 388.85; 435/7

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)
- U.S. : 424/130.1, 133.1, 155.1, 156.1; 530350, 387.3, 388.85; 435/7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 6,468,528 B1 (MAK ET AL) 22 October 2002 (22/10/02), see entire document, especially column 4, 5, 6, 7.</td>
<td>1, 3, 5-11, 26-27, 32-33</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30-31</td>
</tr>
<tr>
<td>Y</td>
<td>US 6,156,321 A (THORPE ET AL) 05 December 2000 (05/12/00), see entire document, especially column 7, line 34-36.</td>
<td>30-31</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

*[A]* Special categories of cited documents:

- *[A]* document defining the general state of the art which is not considered to be of particular relevance

- *[E]* earlier application or patent published on or after the international filing date

- *[L]* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

- *[O]* document referring to an oral disclosure, use, exhibition or other means

- *[P]* document published prior to the international filing date but later than the priority date claimed

- *[X]* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *[Y]* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- *"* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more of the other documents, such combination being obvious to a person skilled in the art

- *"&"* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

Name and mailing address of the ISA/US
- Mail Stop PCT, Attn: ISA/US Commissioner for Patents
- P.O. Box 1450
- Alexandria, Virginia 22313-1450
- Facsimile No. (703) 305-3230

Authorized officer: [Signature]

Christopher Yuen

Telephone No. 703-308-0196

Form PCT/ISA/210 (second sheet) (January 2004)
Continuation of B. FIELDS SEARCHED Item 3:
CAPLUS, MEDLINE, WEST, BIOSIS, PIR, SWISS PROT
Search terms: inventor name, anti-IL-13, antibody, SEQ ID Nos, single-chain, Hodgkin's lymphoma, 228B/C, 228A-4.